Investigación

Leucemia y hemopatías pediátricas

Buscador de publicaciones

Publicaciones

  • Kobialka P, Sabata H, Vilalta O, Gouveia L, Angulo-Urarte A, Muixí L, Zanoncello J, Muñoz-Aznar O, Gene-Olaciregui N, Fanlo L, Esteve-Codina A, Lavarino C, Javierre BM, Celis-Passini V, Rovira-Zurriaga C, López-Fernández S, Baselga E, Mora J, Castillo SD and Graupera M.

    The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib

    EMBO Molecular Medicine . 14(7): . Nº de citas: 26

    [doi:10.15252/emmm.202115619]

  • Bueno C, Barrena S, Bataller A, Ortiz-Maldonado V, Elliott N, O'Byrne S, Wang G, Rovira M, Gutierrez-Agüera F, Trincado JL, Gonzalez M, Morgades M, Sorigué M, Barcena P, Zanetti SR, Torrebadell-Burriel M, Vega-García N, Rives-Solà S, Mallo M, Sole F, Mead AJ, Roberts I, Thongjuea S, Psaila B, Juan-Otero M, Delgado J, Urbano-Ispizua Á, Ribera JM, Orfao A, Roy A and Menéndez P.

    CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

    Blood . 140(1): 38-44. Nº de citas: 20

    [doi:10.1182/blood.2021014840]

  • García-Gerique L, Garcia-López M, Garrido- García A, Gómez-González S, Torrebadell-Burriel M, Prada-Varela E, Pascual-Pastó G, Muñoz-Aznar O, Pérez-Jaume S, Lemos I, Salvador-Marcos N, Vilà-Ubach M, Doncel-Requena A, Suñol M, Carcaboso AM, Mora J and Lavarino C.

    MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment

    BMC Cancer . 22(1): 669-669. Nº de citas: 10

    [doi:10.1186/s12885-022-09725-8]

  • Pennesi E, Michels N, Brivio E, van der Velden VHJ, Jiang Y, Thano A, Ammerlaan AJC, Boer JM, Beverloo HB, Sleight B, Chen Y, Vormoor-Bürger B, Rives-Solà S, Bielorai B, Rössig C, Petit A, Rizzari C, Engstler G, Starý J, Bautista Sirvent FJ, Chen-Santel C, Bruno B, Bertrand Y, Rialland F, Plat G, Reinhardt D, Vinti L, Von Stackelberg A, Locatelli F and Zwaan CM.

    Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

    Leukemia . 36(6): 1516-1524. Nº de citas: 30

    [doi:10.1038/s41375-022-01576-3]

  • Laetsch TW, Maude SL, Balduzzi A, Rives-Solà S, Bittencourt H, Boyer MW, Buechner J, De Moerloose B, Qayed M, Phillips CL, Pulsipher MA, Hiramatsu H, Tiwari R and Grupp SA.

    Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia

    Leukemia . 36(6): 1508-1515. Nº de citas: 20

    [doi:10.1038/s41375-022-01550-z]

  • Ruiz-Llobet A, Gassiot S, Sarrate E, Zubicaray J, Dapena JL, Rives-Solà S, Sevilla J, Menárguez López Á, Panesso Romero M, Montoya C, Vagace JM, Molina Hurtado JR, García-Morín M, García Abós M, Mendoza Sánchez MC, Lendínez F, Palomo Moraleda P, Tallón M, González B, Urrutia E, Serna JV, Peláez Pleguezuelos I, Martínez Merino M, Ramos Elbal E, Orellana E, Benítez Muñoz H and Berrueco R.

    Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013

    JOURNAL OF THROMBOSIS AND HAEMOSTASIS . 20(6): 1390-1399. Nº de citas: 8

    [doi:10.1111/jth.15699]

  • Ortiz-Maldonado V, Alonso-Saladrigues A, Español-Rego M, Martínez-Cibrián N, Faura A, Magnano L, Català-Temprano A, Benítez-Ribas D, Giné E, Díaz-Beyá M, Correa JG, Rovira M, Montoro-Lorite M, Martínez-Roca A, Rodríguez-Lobato LG, Cabezón R, Cid J, Lozano M, Garcia-Rey E, Conde N, Pedrals G, Rozman M, Torrebadell-Burriel M, Setoain X, Rodríguez S, Esteve J, Pascal M, Urbano-Ispizua Á, Juan-Otero M, Delgado J and Rives-Solà S.

    Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease

    AMERICAN JOURNAL OF HEMATOLOGY . 97(6): 731-739. Nº de citas: 7

    [doi:10.1002/ajh.26519]

  • Luque J, Mendes I, Gómez B, Morte B, de Heredia ML, Herreras E, Corrochano V, Bueren J, Gallano P, Artuch-Iriberri R, Fillat C, Pérez-Jurado LA, Montoliu L, Carracedo Á, Millán JM, Webb SM, Palau F, CIBERER Network and Lapunzina P.

    CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiative

    CLINICAL GENETICS . 101(5-6): 481-493. Nº de citas: 8

    [doi:10.1111/cge.14113]

  • Vicente-Garces C, Esperanza-Cebollada E, Montesdeoca S, Torrebadell-Burriel M, Rives-Solà S, Dapena JL, Català-Temprano A, Conde N, Camós-Guijosa M and Vega-García N.

    Technical Validation and Clinical Utility of an NGS Targeted Panel to Improve Molecular Characterization of Pediatric Acute Leukemia

    Frontiers in Molecular Biosciences . 9: 854098-854098. Nº de citas: 4

    [doi:10.3389/fmolb.2022.854098]

  • Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz MJ, Campbell M, Cario G, Cazzaniga G, Escherich G, Harrison CJ, Heyman M, Hunger SP, Kiss C, Liu HC, Locatelli F, Loh ML, Manabe A, Mann G, Pieters R, Pui CH, Rives-Solà S, Schmiegelow K, Silverman LB, Stary J, Vora A and Brown PA.

    Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium.

    Blood . 139(12): 1785-1793. Nº de citas: 30

    [doi:10.1182/blood.2021012328]